(Q36973830)

17 August 2017

1 reference

title

New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer (English)

1 reference

17 August 2017

0 references

1 reference

4

Pierre I Karakiewicz

1 reference

17 August 2017

1

Shahrokh F Shariat

1 reference

17 August 2017

2

Jose A Karam

1 reference

17 August 2017

3

Vitaly Margulis

1 reference

17 August 2017

17 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

101

1 reference

17 August 2017

675-683

1 reference

17 August 2017

6

1 reference

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Prostate specific antigen density of the transition zone for early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Free prostate-specific antigen in serum is becoming more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

The new human tissue kallikrein gene family: structure, function, and association to disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Early identification of individuals with prostate cancer in negative biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

EPCA-2: a highly specific serum marker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Interleukin-6 is an autocrine growth factor in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Interleukin-6: a candidate mediator of human prostate cancer morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Serum chromogranin-A in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.07283.X

10.1111/J.1464-410X.2007.07283.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17941930